Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks

Multiple Sclerosis Clinical Trial

— TERI-PK  

Official title:

Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04410965
• Other study ID #: BDR16019
• Secondary ID: U1111-1233-0136
• Status: Completed
• Phase: Phase 4
• Start date: May 20, 2020
• Est. completion date: July 12, 2021

Study information

• Verified date: April 2022
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

Evaluate the relationship between ABCG2 mutation (rs2231142) and teriflunomide exposure, during 6-month treatment with teriflunomide 14 mg

Secondary Objective:

Characterize the safety (AEs, such as ALT enhancement, hair thinning, diarrhea, nausea, etc.) during 6-month treatment with teriflunomide

Description:

Study duration per participant is approximately 28 weeks including a 24-week treatment period

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: July 12, 2021
• Est. primary completion date: July 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion criteria:

Participants are eligible to be included in the study only if all the following criteria apply:

• Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent.

• Participants EDSS score = 5.5 according to the diagnosis of the neurologist (using the 2017 Revised McDonald Diagnostic Criteria for MS) and upon treatment initiation with teriflunomide according to the approved product information in China.

• Participants will be genotyped for the rs2231142 mutation, enrolled 80 participants should include: 40 wildtype patients, 40 patients with ABCG2 (rs2231142) mutation

• Male and/or female participants:

• Male participants: A male participant must agree to use contraception during the intervention period and undergo the accelerated eliminated procedure after the last dose of study intervention and refrain from donating sperm during this period.

• Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to follow the contraceptive guidance during the intervention period and undergo the accelerated elimination procedure (if necessary) after the last dose of study intervention.

• Participants who has signed written informed consent prior to entering the screening phase of the study

Exclusion criteria:

Participants are excluded from the study if any of the following criteria apply:

• Participant not willing /being able to complete the questionnaires and examination.

• Participants who have taken leflunomide within 2 years prior to screening.

• Participants who have taken teriflunomide within 2 years prior to screening.

• Participants with severe hepatic impairment, including active hepatitis B/C diagnosed.

• Known history of active tuberculosis (TB) or latent TB infection not adequately treated, either diagnosed by standard medical practice or guidelines.

• Relapse within 30 days prior to enrollment.

• Participants who have any contraindications to AUBAGIO according to the local product insert leaflet.

• History of a hypersensitivity of teriflunomide, leflunomide, or any the inactive ingredients in Aubagio.

• Human immunodeficiency virus (HIV) positive patients.

• Participants treated with:

• glatiramer acetate, interferons, or dimethyl fumarate within 1 month prior to enrollment.

• fingolimod, or intravenous immunoglobulins within 3 months prior to enrollment.

• natalizumab, other immunosuppressant or immunomodulatory agents, such as cyclophosphamide, azathioprine, cyclosporine, methotrexate, mycophenolate, within 24 weeks prior to enrollment.

• cladribine or mitoxantrone within 2 years prior to enrollment.

• adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 2 weeks prior to enrollment.

• Participant treated with BCRP inhibitors (such as cyclosporine, eltrombopag, gefitinib).

• Participant not suitable for participation, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

• Any specific situation during study implementation/course that may rise ethics considerations.

• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Multiple Sclerosis

Intervention

Drug:
• TERIFLUNOMIDE
Pharmaceutical form:tablet Route of administration: oral

Locations

Country	Name	City	State
China	Investigational Site Number	China

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PK exposure: Cmax	PK exposure Cmax will be estimated by PopPK analysis.	From Week 8 to Week 24
Primary	PK exposure: AUCtau	PK exposure AUCtau will be estimated by PopPK analysis	From Week 8 to Week 24
Secondary	Participants with Serious Adverse Events and Adverse Events		Screening to Week 24